Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | JAK3 | P52333 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29052149 | 0.91 | ADORA2A (0.49) | ADORA2AADORA2BADORA1RETJAK2 | |
| SCHEMBL29781034 | 0.91 | ADORA2A (0.49) | ADORA2AADORA2BADORA1RETJAK2 | |
| SCHEMBL19476294 | 0.85 | RET (0.48) | RETJAK2JAK3JAK1HDAC1 | |
| SCHEMBL15826969 | 0.84 | PIK3CD (0.51) | ADORA2AADORA2BADORA1RETJAK2 | |
| SCHEMBL21293809 | 0.82 | ADORA2A (0.48) | ADORA2AADORA2BADORA1RETJAK2 | |
| SCHEMBL19623303 | 0.82 | ADORA2A (0.48) | ADORA2AADORA2BADORA1RETHDAC1 | |
| SCHEMBL19476278 | 0.82 | ADORA2A (0.49) | ADORA2AADORA2BADORA1RETJAK2 | |
| SCHEMBL29780904 | 0.82 | JAK2 (0.46) | ADORA2AADORA2BADORA1RETJAK2 | |
| SCHEMBL29052236 | 0.82 | JAK2 (0.46) | ADORA2AADORA2BADORA1RETJAK2 | |
| SCHEMBL29052129 | 0.80 | JAK2 (0.45) | ADORA2AADORA2BADORA1RETJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY INC. (US) | 2020-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | ADORA2A 4466/4885ADORA2B 4482/4885ADORA1 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.